Loading…
Loading…
Sentiment · FY2026 Q1
| Analyst | Firm | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| A.J. Rice | UBS | 6 | 0% |
| Ben Hendrix | RBC Capital Markets | 6 | 17% |
| Ann Hynes | Mizuho Securities | 6 | 0% |
| Justin Lake | Wolfe Research | 6 | 0% |
| Steve Baxter | Wells Fargo | 5 | 0% |
| Erin Wright | Morgan Stanley | 5 | 0% |
| Andy Mok | Barclays | 5 | 0% |
| Josh Raskin | Nephron Research | 5 | 0% |
| Mike Ha | Robert W. Baird | 4 | 50% |
| Kevin Fischbeck | Bank of America | 4 | 25% |
| Firm | Analysts | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| Wolfe Research | 1 | 6 | 0% |
| Bank of America | 3 | 6 | 17% |
| Mizuho Securities | 1 | 6 | 0% |
| RBC Capital Markets |
| 1 |
| 6 |
| 17% |
| UBS | 1 | 6 | 0% |
| Morgan Stanley | 1 | 5 | 0% |
| Barclays | 1 | 5 | 0% |
| Nephron Research | 1 | 5 | 0% |
Humana delivered a Q1 performing in line to better than expectations across all early indicators, with revenue growing 23% year-over-year as the approximately 1 million new MA members contributed their first full quarter. The 2027 bid strategy prioritized margin trajectory to at least 3% by 2028, and Stars BY28 tracking was on track with BY29 showing strong early starts. Management maintained the at-least-$9 adjusted EPS guidance for 2026 with IBNR reserving up 35% versus 22% membership growth, reflecting prudent conservatism.
Margin | Competitive Dynamics | Cost Pressure | Subscriber Growth | Regulation Policy | Guidance Reliability | Capex Investment | Revenue Growth | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 6 | 5 | 4 | 1 | 6 | 4 | 2 | |
| 2025Q1 | 7 | 2 | 4 | 3 | 4 | 4 | 1 | 3 |
| 2025Q2 | 2 | 5 | 4 | 4 | 5 | 2 | 1 | 3 |
| 2025Q3 | 10 | 7 | 1 | 7 | 3 | |||
| 2025Q4 | 9 | 6 | 4 | 5 | 2 | 2 | 2 | |
| 2026Q1 | 6 | 3 | 8 | 2 | 1 | 1 | 1 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Margin | 6 | 7 | 2 | 10 | 9 | 6 |
| Competitive Dynamics | 5 | 2 | 5 | 7 | 6 | 3 |
| Cost Pressure | 4 | 4 | 4 | 1 | 4 | 8 |
| Subscriber Growth | 1 | 3 | 4 | 7 | 5 | 2 |
| Regulation Policy | 6 | 4 | 5 | 3 | 2 | 1 |
| Guidance Reliability | 4 | 4 | 2 | 2 | 1 | |
| Capex Investment | 2 | 1 | 1 | 2 | 1 | |
| Revenue Growth | 3 | 3 | 1 |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
HUM Humana | 7 | +23.5% | |
| CI Cigna | 8 | +4.6% | |
| CNC Centene Corporation | 9 | +7.1% | |
| CVS CVS Health | 9 | +6.2% | |
| ELV Elevance Health | 7 | +2.6% | |
| UNH UnitedHealth Group Incorporated | 7 | +2.0% |